Comparing bioAffinity Technologies (NASDAQ:BIAF) & Data Knights Acquisition (NASDAQ:DKDCA)

Data Knights Acquisition (NASDAQ:DKDCA) and bioAffinity Technologies (NASDAQ:BIAF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Volatility and Risk

Data Knights Acquisition has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, bioAffinity Technologies has a beta of 3.93, indicating that its share price is 293% more volatile than the S&P 500.

Profitability

This table compares Data Knights Acquisition and bioAffinity Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Data Knights Acquisition	N/A	N/A	-5.55%
bioAffinity Technologies	-313.34%	-107.20%	-84.10%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Data Knights Acquisition and bioAffinity Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Data Knights Acquisition	0	0	0	0	N/A
bioAffinity Technologies	0	0	0	0	N/A

Institutional & Insider Ownership

35.3% of Data Knights Acquisition shares are owned by institutional investors. Comparatively, 1.6% of bioAffinity Technologies shares are owned by institutional investors. 45.7% of Data Knights Acquisition shares are owned by insiders. Comparatively, 44.3% of bioAffinity Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Data Knights Acquisition and bioAffinity Technologies’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Data Knights Acquisition	N/A	N/A	$340,000.00	($0.19)	-3.16
bioAffinity Technologies	$2.53 million	11.78	-$7.94 million	($0.90)	-2.88

Data Knights Acquisition has higher earnings, but lower revenue than bioAffinity Technologies. Data Knights Acquisition is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Data Knights Acquisition beats bioAffinity Technologies on 7 of the 10 factors compared between the two stocks.

About Data Knights Acquisition

Data Knights Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. Data Knights Acquisition Corp. was incorporated in 2021 and is based in Frome, the United Kingdom.

About bioAffinity Technologies

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.